Medical Research Finder

Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

© 2026 meRfi®

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

AuthorsReferences (Sources)

meRfi® AI Chat

Erlotinib & Non-small-cell lung cancer (NSCLC) (EGFR m)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Register for a free trial

Navigation

Contents

Erlotinib is approved by both the FDA and EMA for the treatment of Non-small-cell lung cancer (NSCLC) (EGFR m), specifically for tumors harboring exon 19 deletions or exon 21 (L858R) substitution mutations.
Piperdi & Perez-Soler 2012 Drugs 72(Suppl 1(0 1)): 11-9
Khozin et al. 2014 Oncologist 19(7): 774-9
Markóczy et al. 2018 BMC Cancer 18(1): 598

Neoadjuvant erlotinib was well tolerated and may improve the radical resection rate in this patient population.
Xiong et al. 2019

The primary end point of objective response rate …

References (Sources)

Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Prospective, Single-Arm, Phase II Study
Xiong et al. 2019
Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial
Markóczy et al. 2018 BMC Cancer 18(1): 598
Erlotinib versus standard chemotherapy as ﬁrst-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised Phase III trial
Rosell et al. 2012 Lancet Oncol 13: 239-246
Moving towards molecular-guided treatments: erlotinib and clinical outcomes in non-small-cell lung cancer patients
Santarpia et al., 2013
Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
Soria et al. 2018 NEJM 378: 113-125
Role of erlotinib in the treatment of non-small cell lung cancer: clinical outcomes in wild-type epidermal growth factor receptor patients
Piperdi & Perez-Soler 2012 Drugs 72(Suppl 1(0 1)): 11-9
U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations
Khozin et al. 2014 Oncologist 19(7): 774-9

AI Chat

7/1/2026

Chat with our artificial intelligence: